AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

PCGH ZDP PLC

Earnings Release May 18, 2020

4979_ir_2020-05-18_90e93e2e-dc6a-494a-9451-848bff64d54a.html

Earnings Release

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

RNS Number : 1198N

PCGH ZDP PLC

18 May 2020

PCGH ZDP PLC

Legal Entity Identifier: 5493004C3YRF9HEVQI09

Half-Year Report and Financial Statements for the half year ended 31 March 2020

COMPANY INFORMATION

PCGH ZDP Plc (the 'Company') is a public limited company incorporated in England and Wales on 30 March 2017, with registration number 10700107. The principal legislation under which the Company operates is the Companies Act 2006. The Company's zero dividend preference (ZDP) shares have a standard listing on the London Stock Exchange.

For further information please contact: Tracey Lago FCG

Company Secretary

Polar Capital Global Healthcare Trust Plc
Tel: 020 7227 2700

INTERIM MANAGEMENT REPORT

for the half year ended 31 March 2020

This interim management report is provided in accordance with the Disclosure Guidance and Transparency Rules (DTR) 4.2.7 and 4.2.8.

The Company is a public limited company with the sole purpose of issuing zero dividend preference (ZDP) shares and advancing the proceeds of the issue, by way of a loan, to the parent company. The Company is managed by a board of non-executive directors and the day to day operations are delegated to the Investment Manager, Polar Capital LLP. The Company's entire ordinary share capital is owned by the parent company while the ZDP shares have a standard listing on the London Stock Exchange. The parent company, Polar Capital Global Healthcare Trust Plc (PCGH) and the Company form the Group (the Group).

The sole objective of the Company is to repay the ZDP shareholders, on 19 June 2024, their entitlement to 122.99 pence per ZDP share. The performance of the Company in meeting this objective is directly linked to the performance of the parent company. To meet such objective, the parent company has provided an undertaking to the Company, whereby any shortfall between the final capital entitlement of 122.99 pence per ZDP share and the aggregate principal amount and interest due pursuant to the undertaking will be met in full by the parent company.

Directors

The Directors who served in office during the six months under review are as follows:

·      Lisa Arnold (appointed Chairman on 26 February 2020)

·      Neal Ransome

·      Andrew Fleming (Appointed 1 December 2019)

·      Jeremy Whitley (Appointed 1 December 2019)

·      James Robinson (retired 26 February 2020)

·      Anthony Brampton (retired 26 February 2020)

All of the Directors are also serving directors of the parent company and therefore have an indirect interest in the loan and undertaking entered into by the Company and parent.

Principal Risks and Uncertainties

Subject to the impact of the COVID-19 pandemic, there have been no changes to the risks and uncertainties within the six months under review to those reported in the last annual report, and there were no events or otherwise during the period under review which had any significant effect on the Company, its objective or purpose. The uncertainty surrounding Brexit has now reduced as we move into the transition phase. The COVID-19 pandemic is, of course, having a very substantial impact on the global economy, and this will affect the Company, its parent company and the performance of the parent company's underlying investments.

The board acknowledges its ultimate responsibility for managing the risks associated with the Company. The principal risks and uncertainties as identified by the Board are detailed below:

Capital Value:

The primary risk to the ZDP shareholders is that the assets of the Company are insufficient to repay the final capital entitlement of the ZDP Shares of 122.99 pence per share on the repayment date of 19 June 2024. The payment will be dependent on the parent company's ability to comply with its obligations under the loan and the undertaking.

Investment tenure:

There is a risk that there may not be a liquid secondary market for the ZDP shares. The investment should therefore be regarded as long-term in nature and should not be considered a suitable short-term investment.

Going Concern and Future Developments

In connection with new risks presented by the COVID-19 pandemic the Board has undertaken additional financial analysis and engaged with the Investment Manager of the parent Company to review the results of such. Having carried out the additional testing, and continuation of the regular monitoring of the financial position of the Company and Group, the Board confirms that there continues to be a reasonable expectation that there are adequate resources to continue in operational existence for the foreseeable future. Accordingly, the Board continues to adopt the going concern basis in preparing the financial results of the Company. The Company does not have, and does not expect to have, any other business interests, and the current activities of the Company are expected to continue until the scheduled ZDP Repayment Date of 19 June 2024 at which time the Company will enter into voluntary liquidation.

Statement of Directors' Responsibilities

The Directors of PCGH ZDP Plc, confirm to the best of their knowledge that:

•           The condensed set of financial statements has been prepared in accordance with IAS34 Interim Financial Reporting as adopted by the European Union and gives a true and fair view of the assets, liabilities, financial position and profit or loss of the Company for the six months ended 31 March 2020;

•           The Interim Management Report includes a fair review of the information required by the Disclosure Guidance and Transparency Rules 4.2.7R and 4.2.8R;

The half year financial report for the six-month period to 31 March 2020 has not been audited or reviewed by the Auditors. The half year financial report was approved by the Board on 15 May 2020.

Approved by the Board of Directors and signed on its behalf by:

Lisa Arnold

Chairman

15 May 2020

STATEMENT OF COMPREHENSIVE INCOME

For the half year ended 31 March 2020

(Unaudited) (Unaudited) (Audited)
Half year ended Half year ended Year ended
31 March 2020 31 March 2019 30 September 2019
Total Total Total
Return Return Return
Notes £ £ £
Loan interest 2 421,937 410,517 828,449
Contribution from parent 3 89,339 84,506 171,935
Total income 511,276 495,023 1,000,384
Total expenses - - -
Profit before finance costs and tax 511,276 495,023 1,000,384
Finance costs
Appropriation to ZDP shares 4 (511,276) (495,023) (1,000,384)
Total finance costs (511,276) (495,023) (1,000,384)
Result before taxation - - -
Taxation - - -
Net result for the period and total comprehensive income
- - -

The amounts dealt with in the Statement of Comprehensive Income are all derived from continuing activities.

The notes to follow form part of these financial statements.

STATEMENT OF CHANGES IN EQUITY

For the half year ended 31 March 2020

(Unaudited)

Half year ended 31 March 2020
Called up share capital

£
Capital reserve

£
Total equity

£
Total equity at 1 October 2019 50,000 - 50,000
Result and total comprehensive income for the half year ended 31 March 2020 - - -
Total equity at 31 March 2020 50,000 - 50,000
(Unaudited)

Half year ended 31 March 2019
Called up share capital

£
Capital reserve

£
Total equity

£
Total equity at 1 October 2018 50,000 - 50,000
Result and total comprehensive income for the half year ended 31 March 2019 - - -
Total equity at 31 March 2019 50,000 - 50,000
(Audited)

 Year ended

30 September 2019
Called up share capital

£
Capital reserve

£
Total equity

£
Total equity at 1 October 2018 50,000 - 50,000
Result and total comprehensive income for the year ended 30 September 2019 - - -
Total equity at 30 September 2019 50,000 - 50,000

The notes to follow form part of these financial statements.

BALANCE SHEET

As at 31 March 2020

(Unaudited) (Unaudited) (Audited)
31 March 2020 31 March 2019 30 September 2019
£ £ £
Non-current assets
Loan to parent company 34,884,100 33,867,463 34,372,824
Current assets
Cash and cash equivalents 50,000 50,000 50,000
Total assets 34,934,100 33,917,463 34,422,824
Non-current liabilities
Zero dividend preference shares (34,884,100) (33,867,463) (34,372,824)
Total liabilities (34,884,100) (33,867,463) (34,372,824)
Net assets 50,000 50,000 50,000
Equity attributable to equity shareholders
Called up share capital 50,000 50,000 50,000
Capital reserve - - -
Total equity 50,000 50,000 50,000

These financial statements of PCGH ZDP Plc were approved and authorised for issue by the Board of Directors on 15 May 2020. They were subsequently signed by:

Lisa Arnold

Chairman

The notes to follow form part of these financial statements.

CASH FLOW STATEMENT

For the half year ended 31 March 2020

(Unaudited) (Unaudited) (Audited)
Half Year Ended Half Year Ended Year Ended
31 March 2020 31 March 2019 30 September 2019
£ £ £
Cash flows from operating activities
Profit before finance costs and taxation 511,276 495,023 1,000,384
Net cash inflow from operating activities 511,276 495,023 1,000,384
Cash flows from financing activities
Increase in payables (511,276) (495,023) (1,000,384)
Net cash outflow from financing activities (511,276) (495,023) (1,000,384)
Net increase in cash and cash equivalents - - -
Cash and cash equivalents at the beginning of the period 50,000 50,000 50,000
Cash and cash equivalents at the end of the period 50,000 50,000 50,000

The notes to follow form part of these financial statements.

NOTES TO THE FINANCIAL STATEMENTS

For the half year ended 31 March 2020

1.   General Information

The Company's financial statements have been prepared under the historical cost convention modified to include the revaluation of certain investments. In line with the Company's parent, the financial statements have been prepared in accordance with International Financial Reporting Standards (IFRS), which comprise standards and interpretations approved by the International Accounting Standards Board (IASB) and International Accounting Standards Committee (IASC), as adopted by the European Union, and with those parts of the Companies Act 2006 applicable to companies under IFRS.

The financial information in this half year report does not constitute statutory accounts as defined in section 434 of the Companies Act 2006

The financial information for the half year ended 31 March 2020 and 31 March 2019 has not been audited. The figures and financial information for the year ended 30 September 2019 are an extract from the latest published accounts and do not constitute statutory accounts for that period.

Full statutory accounts for the year ended 30 September 2019, prepared under IFRS, including the report of the auditors which was unqualified, did not draw attention to any matters by way of emphasis and did not contain a statement under section 498 of the Companies Act 2006, have been delivered to the Registrar of Companies.

The Company's accounting policies have not varied from those described in the financial statements for the year ended 30 September 2019.

The Company's presentational currency is pounds sterling. Pounds sterling is also the functional currency of the Company because it is the currency of the primary economic environment in which the Company operates.

2.   Loan interest

Under a Loan Agreement the gross initial ZDP Placing proceeds have been lent to the Parent, Polar Capital Global Healthcare plc. The loan agreement provides that interest will accrue on the loan at a daily rate of 2.5% compounded annually.

3.   Contribution from parent

The contribution represents the additional funding required from the parent company to meet the entitlement due to the ZDP shareholders at the period end. The contribution from the parent as at  31 March 2020 was £89,339 (31 March 2019: £84,506 and 30 September 2019: £171,935).

4.   Finance costs                                                                          

The ZDP shares are designed to provide a pre-determined capital growth from their original issue price of 100p on 19 June 2017 to a final capital entitlement of 122.99 on 20 June 2024. The initial capital of 100p at 19 June 2017 will increase at an interest rate of 3% compounding annually. The provision for the capital growth entitlement on the ZDP shares is included as a finance cost.

5.   Net asset value per ZDP share 

(Unaudited) (Unaudited) (Audited)
Half Year Ended Half Year Ended Year Ended
31 March 2020 31 March 2019 30 September 2019
Calculated entitlement of ZDP shareholders (£) 34,884,100 33,867,463 34,372,824
ZDP shares in issue at the end of the year 32,128,437 32,128,437 32,128,437
Net asset value per ZDP share (pence) 108.58 105.41 106.99

6.   Related party

The Company has provided an interest-bearing loan to its parent company, Polar Capital Global Healthcare Trust Plc. The loan is carried at amortised cost, which represents the initial cost of the loan plus accrued interest and any contribution due from the parent to meet the total ZDP entitlement. As at 31 March 2020, £34,884,100 was due from the parent company in respect of the loan (31 March 2019: £33,867,463 and 30 September 2019: £34,372,824).

HALF YEAR REPORT 

The Company has opted not to post half year reports to shareholders. Copies of this announcement will be available from the Company Secretary at the Registered Office, 16 Palace Street, London SW1E 5JD and from the parent company's website at www.polarcapitalhealthcaretrust.com

Neither the contents of the Company's website nor the contents of any website accessible from the hyperlinks on the Company's website (or any other website) is incorporated into or forms part of this announcement.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

IR GPURPAUPUGRA

Talk to a Data Expert

Have a question? We'll get back to you promptly.